Markers of bone turnover and pain score values in the placebo group at baseline compared with postplacebo administration
| Parameter . | Baseline . | Postplacebo . | P . |
|---|---|---|---|
| Bone mineral density, g/cm2 | |||
| L1-L4 | 0.77 (0.52-0.99) | 0.80 (0.55-1.02) | .009 |
| Femoral neck | 0.66 (0.48-0.85) | 0.67 (0.47-0.93) | .135 |
| Wrist bone | 0.56 (0.35-0.81) | 0.53 (0.32-0.68) | .016 |
| Bone mineral density, T score | |||
| L1-L4 | −2.50 (−4.00 to −0.90) | −2.30 (−4.90 to −0.60) | .115 |
| Femoral neck | −1.85 (−3.30 to −0.40) | −1.80 (−3.10 to 0.80) | .227 |
| Wrist bone | −3.30 (−8.70 to −0.10) | −3.30 (−8.50 to −0.80) | .05 |
| Bone mineral density, Z score | |||
| L1-L4 | −1.90 (−4.50 to −0.30) | −1.50 (−4.20 to 0.30) | .020 |
| Femoral neck | −0.90 (−2.40 to 0.20) | −0.90 (−2.20 to 1.30) | .025 |
| Wrist bone | −2.60 (−8.30 to 1.30) | −2.65 (−7.50 to 1.00) | .071 |
| Markers of bone resorption | |||
| CTX, ng/mL | 0.14 (0.01-0.34) | 0.19 (0.03-0.49) | <.001 |
| TRACP-5b, U/L | 0.16 (0.04-0.44) | 0.17 (0.09-0.50) | <.001 |
| Markers of bone formation | |||
| bALP , U/L | 11.38 (4.72-34.40) | 15.84 (8.40-38.67) | <.001 |
| OC, ng/mL | 3.36 (0.57-19.60) | 4.22 (0.23-19.36) | .170 |
| Markers of osteoclast activation | |||
| sRANKL, pmol/L | 0.22 (0.05-0.82) | 0.28 (0.09-0.99) | <.001 |
| OPG, pmol/L | 3.97 (0.08-11.12) | 4.99 (0.78-12.12) | <.001 |
| sRANKL/OPG | 0.06 (0.01-1.27) | 0.08 (0.01-0.30) | .057 |
| Markers of osteoblast inhibition | |||
| Sclerostin, pmol/L | 22.9 (3.6-53.8) | 24.8 (4.6-53.9) | <.001 |
| DKK-1, pmol/L | 5.01 (0.11-16.66) | 15.25 (9.14-26.25) | <.001 |
| Pain score | |||
| Huskisson’s visual analog scale, cm | 3.0 (0-5) | 2.8 (0-5) | .356 |
| MGM | 2 (0-4) | 2 (0-3) | .768 |
| Parameter . | Baseline . | Postplacebo . | P . |
|---|---|---|---|
| Bone mineral density, g/cm2 | |||
| L1-L4 | 0.77 (0.52-0.99) | 0.80 (0.55-1.02) | .009 |
| Femoral neck | 0.66 (0.48-0.85) | 0.67 (0.47-0.93) | .135 |
| Wrist bone | 0.56 (0.35-0.81) | 0.53 (0.32-0.68) | .016 |
| Bone mineral density, T score | |||
| L1-L4 | −2.50 (−4.00 to −0.90) | −2.30 (−4.90 to −0.60) | .115 |
| Femoral neck | −1.85 (−3.30 to −0.40) | −1.80 (−3.10 to 0.80) | .227 |
| Wrist bone | −3.30 (−8.70 to −0.10) | −3.30 (−8.50 to −0.80) | .05 |
| Bone mineral density, Z score | |||
| L1-L4 | −1.90 (−4.50 to −0.30) | −1.50 (−4.20 to 0.30) | .020 |
| Femoral neck | −0.90 (−2.40 to 0.20) | −0.90 (−2.20 to 1.30) | .025 |
| Wrist bone | −2.60 (−8.30 to 1.30) | −2.65 (−7.50 to 1.00) | .071 |
| Markers of bone resorption | |||
| CTX, ng/mL | 0.14 (0.01-0.34) | 0.19 (0.03-0.49) | <.001 |
| TRACP-5b, U/L | 0.16 (0.04-0.44) | 0.17 (0.09-0.50) | <.001 |
| Markers of bone formation | |||
| bALP , U/L | 11.38 (4.72-34.40) | 15.84 (8.40-38.67) | <.001 |
| OC, ng/mL | 3.36 (0.57-19.60) | 4.22 (0.23-19.36) | .170 |
| Markers of osteoclast activation | |||
| sRANKL, pmol/L | 0.22 (0.05-0.82) | 0.28 (0.09-0.99) | <.001 |
| OPG, pmol/L | 3.97 (0.08-11.12) | 4.99 (0.78-12.12) | <.001 |
| sRANKL/OPG | 0.06 (0.01-1.27) | 0.08 (0.01-0.30) | .057 |
| Markers of osteoblast inhibition | |||
| Sclerostin, pmol/L | 22.9 (3.6-53.8) | 24.8 (4.6-53.9) | <.001 |
| DKK-1, pmol/L | 5.01 (0.11-16.66) | 15.25 (9.14-26.25) | <.001 |
| Pain score | |||
| Huskisson’s visual analog scale, cm | 3.0 (0-5) | 2.8 (0-5) | .356 |
| MGM | 2 (0-4) | 2 (0-3) | .768 |
Bold values denote statistical significance. Values are expressed as median (range).